VC-backed uniQure files $75m IPO

The company is backed by Coller Capital, Forbion Capital Partners, Advent Venture Partners and Gilde Investment Management. Forbion and Coller are the firm's largest shareholders, holding stakes of 35.6% and 44.5% respectively.

Gilde - through its Gilde Healthcare Partners division - owns a 13.5% shareholding in uniQure, while Advent holds a 6.2% stake.

In November last year, uniQure submitted a confidential F-1 filing to the US Securities and Exchange Commission (SEC) for its planned IPO, as reported by unquote" at the time.

Jefferies, Leerink Swann and Piper Jaffray have been appointed joint bookrunners for the flotation. The company plans on trading on the Nasdaq under the ticker symbol "QURE".

Amsterdam-headquartered uniQure develops human gene-based therapies. Its Glybera product is designed to treat lipoprotein lipase (LPL) deficiency, a mutation in the LPL-coding gene that causes a lack of ability to produce the LPL enzymes needed to break down fatty acids.

For a detailed overview of uniQure's company and funding history by unquote", please click here.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Healthcare
• Benelux
• Netherlands
• Advent Venture Partners
• Coller Capital
• Gilde Investment Management
• IPO